Literature DB >> 27188542

Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Andrea K Viecelli1,2, Elaine M Pascoe2, Kevan R Polkinghorne3,4,5, Carmel M Hawley1,2, Peta-Anne Paul-Brent2, Sunil V Badve2,6,7, Alan Cass8, David W Johnson1,2, Peter G Kerr3,5, Trevor A Mori9, Anish Scaria2, Lai-Seong Hooi10, Loke-Meng Ong11, Ashley B Irish9,12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27188542     DOI： 10.1111/nep.12823

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN： 1320-5358            Impact factor:   2.506


× No keyword cloud information.
  3 in total

Review 1.  Antiplatelet agents for chronic kidney disease.

Authors:  Patrizia Natale; Suetonia C Palmer; Valeria M Saglimbene; Marinella Ruospo; Mona Razavian; Jonathan C Craig; Meg J Jardine; Angela C Webster; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2022-02-28

2.  Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial.

Authors:  Andrea K Viecelli; Kevan R Polkinghorne; Elaine M Pascoe; Peta-Anne Paul-Brent; Carmel M Hawley; Sunil V Badve; Alan Cass; Lai-Seong Hooi; Peter G Kerr; Trevor A Mori; Loke-Meng Ong; David Voss; David W Johnson; Ashley B Irish
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

3.  Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease.

Authors:  Ka-Wai Tam; Mei-Yi Wu; Fahad Javaid Siddiqui; Edwin Sy Chan; Yanan Zhu; Tazeen H Jafar
Journal:  Cochrane Database Syst Rev       Date:  2018-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.